Report      Database

    Hepatitis C (HCV) Market Forecast & Drugs Pipeline Analysis to 2016

    Date: 23 Jan, 2012              Type: Drugs & Pharmaceuticals              Pages: 72

    Hepatitis C (HCV) Market Forecast & Drugs Pipeline Analysis to 2016
    • Electronic Access - Single User License
      $975.00
    • CD-ROM Mail Delivery
      $1,075.00
    • Hard-copy Mail Delivery
      $1,075.00
    • Electronic Access - Multi User License
      $1,500.00

    Hepatitis C virus drug market is experiencing a dramatic near-term growth, by crossing US$ 6 Billion in 2011 and is expected to be more than double of its current figure by 2015. This robust growth will be driven primarily by the launch of novel premium-priced agents that will increase the size of the drug-treated population, mainly as a result of the re-treatment of prior non-responder patients.    
     
    Pegasys, Copegus and Pegintron were the only obtainable drugs in Hepatitis C drug market till May 2011. Pegasys always had more revenue generation in any year compared to Pegintron and is also expected to have higher revenue in future till 2016. However by the end of May 2011, the dynamics of the market has changed after the launch of Incivek and Victrelis. Incivek sale has grown quickly and it garnered around US$ 400 Million by end of 3rd quarter 2011. It is expected that Incivek sales will be slightly less than US$ 4 Billion by 2015. On the other hand Victrelis, which was approved a week before Incivek, is moving along a slower adoption curve. Victrelis has lost its grip into the market and reaped only US$ 31 Million sales by the end of 3rd quarter 2011. 
     
    In respect of these there are many other pipeline drugs, which are currently in clinical trial Phase II or Phase III and expected to be launched by 2014. Pipeline drugs like Setrobuvir (ANA 598), RG-7128, TMC - 435 and Danoprevir are going to be the next game changers in the Hepatitis C drug market. Renub Research report entitled “Hepatitis C (HCV) Market Forecast & Drugs Pipeline Analysis to 2016” is an essential source of information and analysis on the global HCV market. The report identifies the key trends shaping and driving the global HCV market. The report also provides insight into the prevalent competitive landscape, launched HCV drugs present and future performance, yet to be launched HCV drugs forecast. Most importantly, the report provides valuable insight into the pipeline products within the global Hepatitis C sector.
     
     
    What We Have Achieved in this Report
     
    •  Comprehensive situation analysis of the Global Hepatitis C drug market and its dynamics.
    •  Identifying all available drugs, pipeline drugs and their position in clinical trials and quantifying their      
       current and future market potential.
    •  Providing a robust long range value forecast for all available drugs, pipeline drugs and their position in  
       clinical trial.
    •  Providing an understanding of key drivers and restraints and their impact on current and future market  
       scenario.  
     
     
    Competitive Landscape
     
    This section covers the key facts about the major companies that play an important role in Hepatitis C drug market. The companies analyzed in this section are – Merck, Vertex Pharmaceuticals, Roche, Pharmasset, Anadys Pharmaceuticals. All the companies have been analyzed from two points of views. 
     
    1) Strength of the company in Hepatitis C drug market 
    2) Weakness of the company in Hepatitis C drug market.  
     
     
    Data Sources
     
    This report is built using data and information sourced from proprietary databases, secondary research and in-house analysis by Renub Research team of industry experts.
     
    Secondary sources information and data has been collected from various printable and non-printable sources like search engines, News websites, Government Websites, Trade Journals, White papers, Government Agencies, Magazines, Newspapers, Trade associations, Books, Industry Portals, Industry Associations and access to more than 500 paid databases.

    1.    Executive Summary
    2.    Global Hepatitis C Market & Forecast (2004 – 2015)  
    2.1    Merger & Acquisition in Hepatitis C Market (2006 - 2010) 
     
    3.    Hepatitis C Drug Class Market & Future Trends
    3.1    Modified Interferon Alphas Market & Forecast (2004 – 2014) 
    3.2    Nucleoside Analogues & IMPDH Inhibitors Market & Forecast (2004 – 2014) 
    3.3    HCV - Specific Antiviral Market & Forecast (2009 – 2014) 
    3.4    Non Interferon Alfa Immune Modulator Market (2009 – 2014) 
     
    4.    Global – Top Hepatitis C Drugs Market & Forecast
    4.1    Pegasys Sales & Forecast (2005 – 2016) 
    4.2    Pegintron Sales & Forecst (2009 – 2016) 
    4.3    Incivek (Telaprevir) Sales & Forecast (2011 – 2015) 
    4.4    Victrelis (Boceprevir) Sales & Forecast (2011 – 2015) 
     
    5.    Pipeline Drug Forecast Analysis
    5.1    Setrobuvir (ANA598) (Anadys Pharmaceuticals) Sales Forecast (2014 – 2018) 
    5.2    RG-7128 (Pharmasset) Sales Forecast (2014 – 2018) 
    5.3    TMC - 435 (Medivir & Tibotec) Sales Forecast (2014 – 2018) 
    5.4    Danoprevir (Roche) Sales Forecast (2014 – 2018) 
     
    6.    Pipeline Drug Clinical Trial Statement
    6.1    PSI-7977 (Pharmasset) 
    6.2    ABT-333(Abbott & Enanta Pharmaceuticals) 
    6.3    Vaniprevir (MK-7009)(Merck) 
    6.4    BI 201335 (Boehringer Ingelheim) 
    6.5    ABT-450 (Abbott Laboratories) 
    6.6    BMS-650032 (Bristol-Myers Squibb) 
    6.7    Setrobuvir (ANA 598) (Anadys Pharmaceuticals) 
    6.8    Filibuvir (Pfizer) 
    6.9    VX-222 (Vertex) 
    6.10    GS-9190 (Gilead) 
    6.11    Danoprevir(Roche) 
     
    7.    Key Drivers of Growth in Global Hepatitis C Drug Market
    7.1    The Growing Crisis of HIV/HCV Co-infection
    7.2    Rising Number of Illicit Drug Users (Drug Addict) 
    7.3    Rising Number of Injecting Drug Users
    7.4    Unmet Medical Needs

    8.    Challenges in Hepatitis C Drug Market
    8.1    Depression & Quality of Life
    8.2    Initial Diagnosis & Decision to Treat
     
    9.    Competitive Landscape
    9.1    Merck
    9.1.1    Strength
    9.1.2    Weakness
    9.2    Vertex Pharmaceuticals
    9.2.1    Strength
    9.2.2    Weakness
    9.3    Roche Holding Ltd
    9.3.1    Strength
    9.3.2    Weakness
    9.4    Pharmasset, Inc. (Company acquired by GILEAD) 
    9.4.1    Strength
    9.4.2    Weakness
    9.5    Anadys Pharmaceuticals, Inc. (Company acquired by Roche) 
    9.5.1    Strength
    9.5.2    Weakness

    List of Figures:
     
    Figure 2 1: Global – Hepatitis C Market (Million US$), 2004 – 2011
    Figure 2 2: Global – Forecast for Hepatitis C Market (Billion US$), 2012 – 2015
    Figure 3 1: Global – Modified Interferon Alfa Market (Million US$), 2004 – 2011
    Figure 3 2: Global – Forecast for Modified Interferon Alfa Market (Million US$), 2012 – 2014
    Figure 3 3: Global – Nucleoside Analogues & IMPDH Inhibitors Market (Million US$), 2004 – 2011
    Figure 3 4: Global – Forecast for Nucleoside Analogues & IMPDH Inhibitors Market (Million US$), 2012 – 2014
    Figure 3 5: Global – HCV Specific Antiviral Market (Million US$), 2009 – 2011
    Figure 3 6: Global – Forecast for HCV Specific Antiviral Market (Million US$), 2012 – 2014
    Figure 3 7: Global – Non Interferon Alfa Immune Modulator Market (Million US$), 2009 – 2011
    Figure 3 8: Global – Forecast for Non Interferon Alfa Immune Modulator Market (Million US$)
    Figure 4 1: Global – Pegasys Drug Sales (Million US$), 2005 – 2011
    Figure 4 2: Global – Forecast for Pegasys Drug Sales (Million US$), 2012 – 2016
    Figure 4 3: Global – Pegintron Drug Sales (Million US$), 2009 – 2011
    Figure 4 4: Global – Forecast for Pegintron Drug Sales (Million US$), 2012 – 2016
    Figure 4 5: Global – Incivek Drug Sales & Forecast (Million US$), 2nd Qtr 2011, 3rd Qtr 2011, 2011 – 2015 
    Figure 4 6: Global – Victrelis (Boceprevir) Sales & Forecast (Million US$), 2nd Qtr 2011, 3rd Qtr 2011, 2011 – 2015
    Figure 5 1: Global – Forecast for Setrobuvir (ANA598) Drug Sales (Million US$), 2014 – 2018
    Figure 5 2: Global – Forecast for RG - 7128 Market (Million US$), 2014 – 2018
    Figure 5 3: Global – Forecast for TMC-435 Drug Market (Million US$), 2014 – 2018
    Figure 5 4: Global – Forecast for Danoprevir Drug Sales (Million US$), 2014 – 2018
    Figure 7 1: Global – Illicit Drug Users & Problem Drug Users (Million) 2001/02 – 2009/10
    Figure 7 2: Global – Prevalence of Illicit Drug Use & Problem Drug Use (percent), 2001/02 – 2009/2010
    Figure 7 3: Global – Opium Poppy Cultivation (Hectares), 1990, 1995, 2000, 2005 – 2010
    Figure 7 4: Global – Coca Cultivation (Hectares), 1990, 1995, 2000, 2005 – 2010

     
    List of Tables:
     
    Table 2 1: Global – Merger & Acquisition (Million US$) 2009 – 2011
    Table 6 1: PSI – 7977 – Clinical Trials
    Table 6 2: ABT – 333 – Clinical Trials
    Table 6 3: Vaniprevir MK – 7009 – Clinical trials
    Table 6 4: BI 201335 – Clinical Trials
    Table 6 5: ABT-450 – Clinical Trials
    Table 6 6: BMS – 650032 – Clinical Trials
    Table 6 7: ANA 598 – Clinical Trials
    Table 6 8: Filibuvir – Clinical Trials
    Table 6 9: VX-222 – Clinical Trials
    Table 6 10: GS-9190 – Clinical Trials
    Table 6 11: Danoprevir – Clinical Trials
    Table 7 1: Worldwide – HIV/HCV Co-infection Prevalence Rates in Selected Countries, 2008
    Table 7 2: Worldwide – HCV Prevalence among People Who Inject Drugs and Prison Populations in Selected Countries, 2008
    Table 7 3: Region & Sub-region – Illicit Drug Users of Cannabis & Opioid Aged 15 – 64, (Number), 2009
    Table 7 4: Region & Sub-region – Illicit Drug Users of Opiate & Cocaine Aged 15 – 64 (Number), 2009
    Table 7 5: Region & Sub-region – Illicit Drug Users of Amphetamines & Ecstasy Aged 15 – 64 (Number), 2009
    Table 7 6: Global – Hepatitis C Prevalence among Injecting Drug Users (Percent) 
    Table 8 1: Ireland – Predictors of Depressive Disorder Diagnosed Using the SCID – CV
    Table 8 2: Ireland – Illness Related Predictors of Depressive Disorder Diagnosed using the SCID – CV
    Table 9 1: Merck – Key Financials (Million US$) 2008 – 2010
    Table 9 2: Vertex – Key Financials (Million US$), 2008 – 2010
    Table 9 3: Roche – Key Financials (Million US$) 2008 – 2010
    Table 9 4: Pharmasset – Key Financials (Million US$) 2008 – 2010
    Table 9 5: Anadys – Key Financials (Million US$) 2007 – 2009


    Related Products